Lung Health Check Pilot
Official title: The Lung Health Check Pilot
Run by Royal College of Surgeons, Ireland · NCT07099027 · Data updated 2026-11-12
This pilot tries to see if offering a lung health check—including lung function tests and a low-dose CT scan—can find lung cancer early in people aged 55–74 who currently smoke or used to smoke in Ireland.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 55 Years to 74 Years |
| Sex | All |
| Enrollment | 2183 (estimated) |
| Sponsor | Royal College of Surgeons, Ireland Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Dublin) |
| Status | Recruiting |
| Started | May 19, 2025 |
| Main results expected | February 15, 2026 |
| Study ends | January 15, 2028 |
| Registry record updated | August 1, 2025 |
| Trial ID | NCT07099027 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people aged 55–74 who currently smoke or formerly smoked, have a sufficient calculated lung-cancer risk (PLCOM2012 ≥1.51% or LLPv2 ≥2.5%), and are referred by their GP.
✕Probably not a fit
People outside the 55–74 age range, never-smokers, those who had a chest CT in the past 12 months, residents of nursing homes, or those unable to undergo or attend CT visits are unlikely to benefit from this pilot.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The pilot invites people aged 55–74 who are current or former smokers and referred by their GP to undergo a lung health check consisting of lung function tests and a low-dose CT scan. Participants are selected using established lung cancer risk scores (PLCOM2012 ≥ 1.51% or LLPv2 ≥ 2.5%) and are excluded if they had a chest CT in the last 12 months or have recent advanced cancers, recent lung cancer, or cannot undergo non-contrast CT. The programme is delivered at Beaumont RCSI Cancer Centre and focuses on detecting lung cancer before symptoms develop so disease can be treated earlier. This is a feasibility pilot to see if this screening pathway can be implemented in Ireland and to refine processes for larger rollout.
Why it matters
Potential benefit: If successful, the programme could detect lung cancer at an earlier, more treatable stage and thereby reduce deaths from the disease.
How similar studies have gone: Large trials such as the NLST and major European studies have shown low-dose CT screening can reduce lung cancer mortality by about 20–26%, so this approach has proven effectiveness elsewhere.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 55 - 74 years of age 2. Current or former smokers * Current: \>100 cigarettes in lifetime and/or currently tobacco smoking * Former: \>100 cigarettes in lifetime and/or no tobacco smoking \>= 28 days 3. Referred from a GP for the LHC pilot 4. PLCOM2012 ≥ 1.51% or LLPv2 ≥2.5% (Lung Cancer Risk Scores) * Prostate Lung Cancer Colorectal Ovarian (PLCO) \& Liverpool Lung Project Version 2 (LLPv2) Exclusion Criteria: 1. Participant-reported history of chest CT in the last 12 months 2. Inability to undergo non-contrast CT (e.g. \>200 kg body weight, inability to lie flat) 3. Participant reported known diagnosis of other advanced stage cancers 4. Participant reported diagnosis of lung cancer of any stage in the last 5 years 5. Likely non-compliance with study procedures, as determined by the participant i) Unable to provide informed consent ii) Inability to attend study visits 6. Nursing home residents -
Where it's running
-
Beaumont RCSI Cancer Centre
Dublin, Ireland Recruiting
Study contacts
- Principal investigator: Jarushka Naidoo, MD — Beaumont RCSI Cancer Centre
- Study coordinator: Sandra Roche, PhD
- Email: lunghealthcheck@beaumont.ie
- Phone: 018093010
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Patient-specific MRD liquid biopsy for resected NSCLC
This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.
-
Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases
This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.
-
Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies
This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery
This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.
-
HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC
This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.